Review chimeric antigen receptor (CAR) T cell structure, function and current clinical applications
Discuss development of CAR T cells for autoimmune diseases
Describe efforts to utilize CAR T cells for infectious diseases
Description: Chimeric antigen receptor (CAR) T cells, T cells genetically modified to express a hybrid receptor combining B cell receptor specificity with the activation capacity of a T cell receptor, have gained much visibility given their success in treating malignant conditions, especially hematologic malignancies, with otherwise poor prognoses. Given the recent approval by the Food and Drug Administration (FDA) of CAR T cells directed towards CD19 for acute lymphoblastic leukemia (ALL) and diffuse large B cell lymphoma (DLBCL), the status of CAR T cells as a therapeutic option for malignant conditions is recognized. Motivated by this success, efforts to expand the application of this innovative platform of cellular immunotherapy to other conditions are underway. CAR T cells are being developed for use in such conditions as debilitating autoimmune disease, infectious diseases, such as HIV, and in the setting of organ transplantation. This session will focus on exciting developments that attempt to push the potential clinical applications of CAR T cells beyond the sphere of oncology.
Assistant Professor of Pathology and Laboratory Medicine,